Alpha Cognition Inc., a biopharmaceutical company specializing in therapies for neurodegenerative disorders, announced that their partner, China Medical System Holdings Limited $(CMS)$, has received acceptance for their New Drug Application (NDA) by the National Medical Products Administration of China (NMPA). This NDA pertains to ZUNVEYL® (Benzgalantamine), a treatment aimed at mild-to-moderate Alzheimer's dementia. This milestone signifies a critical step toward potentially introducing this innovative therapy to the Asian market. Alpha Cognition is set to benefit from CMS's regulatory and commercial expertise in China and will receive financial gains such as regulatory and sales milestones, and royalties upon ZUNVEYL's approval for marketing in China and other Asian territories.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.